CN Stock MarketDetailed Quotes

688428 InnoCare Pharma

Watchlist
  • 12.66
  • +0.81+6.84%
Market Closed Nov 19 15:00 CST
22.31BMarket Cap-59436P/E (TTM)

About InnoCare Pharma Company

The company is a commercialized biomedical high-tech company. It was co-founded in 2015 by Dr. Cui Jisong, who has rich experience in new drug development and enterprise management, and Academician Shi Yigong, a world-famous structural biologist. We develop innovative drugs for patients with malignant tumors and autoimmune diseases, so that innovative results can benefit more patients. The company is a high-tech innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D, production and commercialization capabilities, focuses on fields such as tumors and autoimmune diseases where there are huge unmet clinical needs, and develops first-of-its-kind or best-in-class drugs with breakthrough potential in the global market. Main products: obutinib, ICP-B04, ICP-248, ICP-B02, ICP-490, ICP-B05, ICP-332, ICP-488, ICP-B02, ICP-923, ICP-723,, ICP-192, etc. ICP-189

Company Profile

Short Name-A诺诚健华
Company NameInnocare Pharma Limited
Listing DateSep 21, 2022
Issue Price11.03
Shares Offered264.65M share(s)
FoundedNov 3, 2015
Chairmanjisong cui
Legal Representativejisong cui
General Managerjisong cui
Secretarybei yuan
Employees1089
ProvinceCayman Islands (the)
Phone(86)1066609999
Office AddressBuilding 8, Yard 8, Life Science Park, Zhongguancun Life Science Park, Changping District, Beijing
Zip Code102206
Registered AddressOgier Global (Cayman) Limited Office 89 Nexus Way Camana Bay Grand Cayman, KY1-9009 Cayman Islands
Fax(86)1060702992
Emailinfo@innocarepharma.com
BusinessNuocheng Jianhua is an innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D and commercialization capabilities, focuses on fields where there is huge unmet clinical demand, such as tumors and autoimmune diseases, and develops best-in-class or first-of-its-kind drugs with breakthrough potential in the global market.

Company Executives

  • Name
  • Position
  • Salary
  • jisong cui
  • Chairman of the Board, Executive Director, CEO, Core Technical Personnel
  • --
  • renbin zhao
  • Executive Director, Core Technical Personnel
  • --
  • yigong shi
  • Non-executive Directors
  • --
  • ronggang xie
  • Non-executive Directors
  • --
  • lan hu
  • Independent Non-Executive Director
  • 360.00K
  • dandan dong
  • Independent Non-Executive Director
  • 80.50K
  • bei yuan
  • Board Secretary
  • --
  • xin fu
  • Chief Financial Officer
  • 412.60K
  • xiangyang chen
  • Chief Technology Officer, Core Technical Personnel
  • --
  • xiangyang zhang
  • Chief Medical Officer
  • 4.80M

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
% Chg

No Data